[{"id":"c81fb89a-a657-47dd-9b13-7d83c2b9a7e0","acronym":"APT-CUBE","url":"https://clinicaltrials.gov/study/NCT05473156","created_at":"2022-07-25T20:54:40.231Z","updated_at":"2024-07-02T16:35:56.496Z","phase":"Phase 1/2","brief_title":"A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients With Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies","source_id_and_acronym":"NCT05473156 - APT-CUBE","lead_sponsor":"AP Biosciences Inc.","biomarkers":" BRAF • MET • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • MET mutation • RET rearrangement • NTRK1 mutation • NTRK3 mutation","tags":["BRAF • MET • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • BRAF V600 • NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • MET mutation • RET rearrangement • NTRK1 mutation • NTRK3 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AP203"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 168","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2027","study_completion_date":" 12/01/2027","last_update_posted":"2023-02-03"}]